Form 4: Amphastar Pharmaceuticals Director Richard Prins Reports Equity Compensation Grant

Amphastar Pharmaceuticals Director Richard K. Prins reported the acquisition of 5,122 restricted stock units and 11,402 stock options as part of his compensation on June 2, 2025.

Summary

• Richard K. Prins, a Director of Amphastar Pharmaceuticals, Inc. (AMPH), reported changes in his beneficial ownership via a Form 4 filing.
• On June 2, 2025, Mr. Prins acquired 5,122 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0. These RSUs are scheduled to vest on June 2, 2026.
• Additionally, on June 2, 2025, he acquired 11,402 stock options with an exercise price of $25.38. These options also vest on June 2, 2026, and have an expiration date of June 2, 2035.
• Following these transactions, Mr. Prins beneficially owns 35,183 shares of Common Stock and 11,402 stock options directly.

Sentiment

Score: 7

Explanation: The filing reports a routine equity compensation grant to a director, which is a positive for aligning interests but does not indicate significant new financial performance or strategic shifts. It's a standard, expected event in corporate governance.

Positives

• The grant of equity compensation to a director aligns their financial interests with those of the shareholders, promoting long-term value creation.
• The acquisition of restricted stock units at a $0 price is a direct grant, typically part of a standard compensation package, providing a direct stake in the company's equity.
• The stock options provide an incentive for the director to contribute to future stock price appreciation, as their value increases with the company's share price.

Future Outlook

The vesting schedule for the granted restricted stock units and stock options on June 2, 2026, indicates a future incentive for the director to remain with the company and contribute to its long-term performance and shareholder value.

Industry Context

This filing represents a routine equity compensation grant to a director, which is a common practice across publicly traded companies in the pharmaceutical industry and other sectors. Such grants are designed to align the interests of executives and directors with those of the shareholders, fostering long-term commitment and performance.

Comparison to Industry Standards

• Equity compensation, including restricted stock units and stock options, is a standard component of director remuneration in the pharmaceutical industry, consistent with practices at comparable companies.
• The specific amounts and vesting schedules are typically determined by compensation committees based on company performance, individual contribution, and market benchmarks for similar roles in the industry, including companies like Pfizer, Merck, or Johnson & Johnson, although specific comparative details are not provided in this filing.

Stakeholder Impact

• Shareholders: The grant of equity compensation aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on general employees is indicated by this specific filing, as it pertains solely to director compensation.

Next Steps

• The 5,122 Restricted Stock Units (RSUs) are scheduled to vest on June 2, 2026.
• The 11,402 Stock Options are scheduled to vest on June 2, 2026, and will expire on June 2, 2035.

Key Dates

Recommendation

Keywords

Amphastar Pharmaceuticals, AMPH, Form 4, SEC filing, insider transaction, beneficial ownership, restricted stock units, RSUs, stock options, equity compensation, director compensation